Resumen de: WO2025212713A1
Methods described herein provide procedures that can be used to rapidly screen drugs for high probability of effectiveness as therapy for amyloid associated neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson's disease, Huntington's disease, and prion-associated diseases by detecting size and/or aggregation of phage incubated with a target compound. The data generated indicate that bacteriophage or phage capsid subunits can switch conformation to a conformation that mimics the neurodegenerative disease-causing conformation of amyloid proteins. This switch has been observed by incubation of bacteriophage T4 with methylene blue, a compound for which literature data indicates has anti-AD activity.
Resumen de: WO2025210040A1
The present invention provides a cell model to study Tau protein related diseases.
Resumen de: MX2025005880A
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
Resumen de: AU2023351193A1
Provided herein are methods and compositions that block Integrin Subunit beta 8 (ITGB8, also known as integrin αvβ8) to treat neurodegenerative diseases associated with microglial impairment including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).
Resumen de: US2025305982A1
The present disclosure provides devices for the detection and/or quantification of neurotoxic amyloid-type protein aggregates, comprising a doxycycline derivative immobilized on an appropriate surface, as well as electrochemical and immunochemical methods associated to the use of such devices.
Resumen de: US2025306037A1
The present disclosure relates to methods useful to identify subjects having an increased risk for conversion to mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and/or stage a subject prior to the onset of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and/or identify subjects with Aβ amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for Aβ amyloidosis, as well as methods for treating subjects diagnosed with Aβ amyloidosis by the methods disclosed herein.
Resumen de: US2025306039A1
Provided are methods of phospho-tau aggregation-based biomarker discovery, and new utilities for discovered biomarkers in Alzheimer's disease (AD) diagnosis, differentiation, and treatment. Novel p-tau sites, p-tau198, p-tauS356, p-tau396, and p-tau422, identified through such methods showed comparable or superior characteristics with established p-tau biomarkers, and identified biomarkers were capable of differentiating AD or mild cognitive impairment (MCI) from cognitively normal controls.
Resumen de: US2025306040A1
Methods for detecting or quantifying amylin-beta amyloid (Aβ) hetero-oligomers (amylin-Aβ aggregate) are provided. Anti-amylin and anti-Aβ antibodies which recognize epitopes that are distinct from high affinity binding sites between amylin peptide and Aβ peptide can be utilized as capture and detection antibodies, respectively, in a sandwich enzyme-linked immunosorbent assay (ELISA) to provide detection and quantification of amylin-Aβ aggregate present in a biological sample, such as blood or brain tissue. Kits useful for the detection and the quantification of amylin-Aβ aggregate are also provided.
Resumen de: US2024197682A1
A method of inhibiting propagation of protein misfolding associated with a neurological disease, is carried out by contacting an environment populated with a propagating amyloid conformation of a protein (prion) associated with a neurological disease with molecules which binds multiple adjacent sites of the protein assemblies and allowing the molecules to bind multiple cites of the protein assemblies; and thereby impeding propagation of the disease-associated conformation of the protein in the environment. Drug/prion complexes are formed and uses of the drugs in detection and treatment of neurodegenerative diseases are disclosed.
Resumen de: WO2024194276A1
The present invention is directed to methods for determining the level of PAM and/or its isoforms and/or fragments thereof in a bodily fluid or a tissue sample using an assay, wherein said assay is comprising at least one binder that is directed to a conformational epitope of PAM, and its use for diagnostic purpose.
Resumen de: WO2025199451A2
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells (MSCs). The methods of treatment involve an administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive or quality-of-life function.
Resumen de: AU2025226659A1
The present disclosure provides methods for blood-based examination useful to identify subjects with Aβ amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for Aβ amyloidosis, as well as methods for treating subjects diagnosed with Aβ amyloidosis by the methods disclosed herein. The present disclosure provides methods for blood-based examination useful to identify subjects with Aß amyloidosis and/or to identify subjects who should or should not undergo further testing or treatment for Aß amyloidosis, as well as methods for treating subjects diagnosed with Aß amyloidosis by the methods disclosed herein. ep h e p r e s e n t d i s c l o s u r e p r o v i d e s m e t h o d s f o r b l o o d - b a s e d e x a m i n a t i o n u s e f u l t o e p i d e n t i f y s u b j e c t s w i t h ß a m y l o i d o s i s a n d o r t o i d e n t i f y s u b j e c t s w h o s h o u l d o r s h o u l d n o t u n d e r g o f u r t h e r t e s t i n g o r t r e a t m e n t f o r ß a m y l o i d o s i s , a s w e l l a s m e t h o d s f o r t r e a t i n g s u b j e c t s d i a g n o s e d w i t h ß a m y l o i d o s i s b y t h e m e t h o d s d i s c l o s e d h e r e i n
Resumen de: US2025298039A1
This disclosure relates to methods for diagnosing and treating a tauopathy, e.g., Alzheimer's disease, in a subject, the methods comprising, in part, identifying one or more post-translation modifications (PTMs) in the subject.
Resumen de: US2025298023A1
A method for diagnosing neurodegenerative diseases, the method including measuring the JNK3 levels in a biological sample selected from plasma, CSF, and saliva. The method also includes measuring P-JNK3.
Resumen de: AU2025226709A1
The present invention relates to an anti-alpha-synuclein antibody preferentially recognizing alpha-synuclein aggregates and a use of detection, diagnosis, and/or treatment or prevention of various diseases caused by accumulation of alpha-synuclein aggregates, or their related symptom diseases by using the anti-alpha-synuclein antibody. The present invention relates to an anti-alpha-synuclein antibody preferentially recognizing alpha-synuclein aggregates and a use of detection, diagnosis, and/or treatment or prevention of various diseases caused by accumulation of alpha-synuclein aggregates, or their related symptom diseases by using the anti-alpha-synuclein antibody. ep e p h e p r e s e n t i n v e n t i o n r e l a t e s t o a n a n t i - a l p h a - s y n u c l e i n a n t i b o d y p r e f e r e n t i a l l y r e c o g n i z i n g a l p h a - s y n u c l e i n a g g r e g a t e s a n d a u s e o f d e t e c t i o n , d i a g n o s i s , a n d o r t r e a t m e n t o r p r e v e n t i o n o f v a r i o u s d i s e a s e s c a u s e d b y a c c u m u l a t i o n o f a l p h a - s y n u c l e i n a g g r e g a t e s , o r t h e i r r e l a t e d s y m p t o m d i s e a s e s b y u s i n g t h e a n t i - a l p h a - s y n u c l e i n a n t i b o d y
Resumen de: US2025295643A1
In various aspects and embodiments the invention provides a method of treating epilepsy in a subject in need thereof, the method comprising providing to the subject an effective amount of an FLNA modulator. In various embodiments, the FLNA modulator is PTI-125 or kartogenin. In various embodiments, the epilepsy is epilepsy associated with focal cortical dysplasia (FCD) type II or tuberous sclerosis complex (TSC).
Resumen de: US2025296997A1
The present disclosure relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
Resumen de: WO2025199015A1
This invention provides skin cell fibroblast- and blood-based methods for determining whether a human subject has a gene expression profile characteristic of AD. This invention also provides related methods for determining whether a demented human subject is afflicted with AD or non-ADD, and for determining whether a non-demented human subject has an increased likelihood of becoming afflicted with AD.
Resumen de: WO2025199495A1
The present invention provides methods and compositions for reducing internalization and/or trafficking of tan in neuronal cells comprising contacting the cells with an effective amount of VLDL receptor antagonist. The invention further provides a method of treating or preventing Alzheimer's disease in a subject in need thereof, comprising administering to the subject an effective amount of a VLDL receptor antagonist.
Resumen de: WO2024107948A1
A process for determining an extent of a central nervous system (CNS) specific neurological condition in a subject including collecting a biological sample of biofluid from the subject and measuring a quantity of a first biomarker, or metabolite of or mRNA corresponding to, the first biomarker from the sample from a dried spot or through a microfluidic device. The biofluid is capillary blood or saliva, which affords ease of collection advantages that are attractive for field-, hospital-, and home-based environments. The process being useful in the diagnosis, care, and management of brain specific abnormal neurological conditions in general, and in particular, to traumatic brain injury (TBI) and (TBI-induced) Alzheimer's disease (AD) and Alexander disease, in which a GFAP mutation is implicated in white matter deterioration.
Resumen de: US2025277799A1
Provided herein are compositions and methods relating to improved assays for establishing Alzheimer's disease. Further provided herein are compositions and methods comprising improved antibodies for assays including immunoassays.
Resumen de: US2025290935A1
Provided in the present application is a marker of Alzheimer's disease, which marker comprises monocyte chemoattractant protein-1 (MCP 1). Further provided in the present application are a method for detecting the marker of Alzheimer's disease, a kit for detecting Alzheimer's disease, and the use of the marker, the detection method and the kit in the screening of a drug for treating Alzheimer's disease.
Resumen de: US2025289874A1
The present application belongs to the technical field of biomedicine, and more particularly, relates to an antibody or an antigen-binding fragment thereof capable of specifically binding to p-tau 217, and a multi-specific molecule, a pharmaceutical composition, and a kit comprising same. The present application further relates to use of the antibody or antigen-binding fragment thereof in preparing a kit or a drug. A monoclonal antibody (for example, 2A7 antibody) according to the present application has a high clinical application value in the detection and prevention of AD and the treatment of AD and other tau protein diseases.
Resumen de: WO2025192800A1
The present invention relates to a pharmaceutical composition for preventing or treating Alzheimer's disease, the composition comprising, as an active ingredient, neural crest-derived nasal turbinate stem cells (NTSCs) expressing SSEA3 and CD105. Treatment with the NTSCs expressing SSEA3 and CD105 or with an NTSC cell line including at least a predetermined proportion of the NTSCs was found to result in remarkably good therapeutic activity against Alzheimer's disease. Therefore, the present invention is expected to be effectively used not only as a composition for preventing or treating Alzheimer's disease in which the composition includes, as an active ingredient, NTSCs expressing SSEA3 and CD105 or an NTSC cell line including at least a predetermined proportion of the NTSCs, but also for uses such as screening of NTSC formulations that can be used to treat Alzheimer's disease, or prediction of the therapeutic efficacy thereof.
Nº publicación: WO2025190329A1 18/09/2025
Solicitante:
UNIV SHANGHAI TECHNOLOGY [CN]
\u4E0A\u6D77\u79D1\u6280\u5927\u5B66
Resumen de: WO2025190329A1
Anti-Aβ drug screening targets and a drug screening method. The screening method uses different Aβ aggregates prepared by simulating the in vivo environment and conditions as targets, to more accurately and effectively screen anti-Aβ candidate drugs; the Aβ targets involved in the screening method are aggregated and incubated under conditions approaching different in vivo microenvironments, and do not require labeling or modification; in addition, the screened drug molecules do not require any modification or labeling, and are not limited to any specific drug class, being widely applicable to different drug types, such as antibodies, peptides and small molecules, truly reflecting the interactions between targets and these drug molecules, greatly reducing the likelihood of problems such as false positives, false negatives or incorrect binding modes.